RxDoctor Payments Data

Tatyana Poviliunas

Psychiatric/Mental Health · Clifton Park, NYNPI 1013503010

Payments from drug & device makers

$1,571in general payments, 2019–2025

Across 70 payments — averaging $22.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$488
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$192
  • Vanda Pharmaceuticals Inc.$168
  • Neurocrine Biosciences, Inc.$146
  • Otsuka America Pharmaceutical, Inc.$146
  • E.r. Squibb & Sons, L.L.C.$102
  • plus $328 from 8 others

What the payments were for

  • Food & beverage$1,47794%
  • Education$946%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,571 in reported general payments places this provider in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$28,424
Medicare patients
48
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate48$171,358
Abilify MaintenaAripiprazole14$41,990
VraylarCariprazine Hcl29$41,181
Risperdal ConstaRisperidone Microspheres24$32,798
RexultiBrexpiprazole17$27,367
AuvelityDextromethorphan Hbr/Bupropion25$26,757
CaplytaLumateperone Tosylate16$25,913
Lurasidone Hcl51$24,995
Aripiprazole215$16,627
Risperidone ErRisperidone Microspheres17$9,487
TrintellixVortioxetine Hydrobromide15$8,110
Quetiapine Fumarate177$5,360
Seroquel XrQuetiapine Fumarate11$5,152
VyvanseLisdexamfetamine Dimesylate12$4,841
Clozapine52$3,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$488$204,15672 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$146$69,35731 claims
Axsome Therapeutics, Inc.Auvelity$14$26,75725 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$192$25,91316 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$31$12,95227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Clifton Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →